Mirae Asset Global Investments Co. Ltd. Sells 11,914 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Mirae Asset Global Investments Co. Ltd. lowered its holdings in Exact Sciences Co. (NASDAQ:EXAS – Get Rating) by 19.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 50,286 shares of the medical research company’s stock after selling 11,914 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Exact Sciences were worth $2,495,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of EXAS. American Century Companies Inc. raised its position in shares of Exact Sciences by 16.5% in the first quarter. American Century Companies Inc. now owns 5,760 shares of the medical research company’s stock valued at $403,000 after purchasing an additional 817 shares during the period. MetLife Investment Management LLC purchased a new position in Exact Sciences during the first quarter valued at approximately $742,000. Panagora Asset Management Inc. grew its stake in Exact Sciences by 4.6% during the first quarter. Panagora Asset Management Inc. now owns 7,281 shares of the medical research company’s stock valued at $509,000 after acquiring an additional 323 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Exact Sciences by 13.5% during the first quarter. Dimensional Fund Advisors LP now owns 448,640 shares of the medical research company’s stock valued at $31,377,000 after acquiring an additional 53,454 shares in the last quarter. Finally, Vontobel Holding Ltd. grew its stake in Exact Sciences by 143.5% during the first quarter. Vontobel Holding Ltd. now owns 22,230 shares of the medical research company’s stock valued at $1,585,000 after acquiring an additional 13,102 shares in the last quarter. Institutional investors own 90.30% of the company’s stock.

Insider Transactions at Exact Sciences

In related news, EVP Sarah Condella sold 1,000 shares of the company’s stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $67.19, for a total transaction of $67,190.00. Following the completion of the sale, the executive vice president now directly owns 86,692 shares in the company, valued at approximately $5,824,835.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, CEO Kevin T. Conroy sold 10,416 shares of the company’s stock in a transaction on Tuesday, February 28th. The shares were sold at an average price of $61.12, for a total transaction of $636,625.92. Following the completion of the sale, the chief executive officer now directly owns 1,207,306 shares in the company, valued at approximately $73,790,542.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Sarah Condella sold 1,000 shares of the company’s stock in a transaction on Monday, April 3rd. The shares were sold at an average price of $67.19, for a total transaction of $67,190.00. Following the sale, the executive vice president now owns 86,692 shares of the company’s stock, valued at $5,824,835.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 50,170 shares of company stock worth $3,320,986. 1.30% of the stock is currently owned by insiders.

Exact Sciences Trading Down 2.0 %

Shares of EXAS opened at $80.83 on Friday. The firm has a market cap of $14.58 billion, a price-to-earnings ratio of -27.68 and a beta of 1.41. The company has a debt-to-equity ratio of 0.77, a quick ratio of 2.63 and a current ratio of 2.97. Exact Sciences Co. has a fifty-two week low of $29.27 and a fifty-two week high of $85.82. The firm has a 50 day moving average price of $69.41 and a 200-day moving average price of $60.70.

Exact Sciences (NASDAQ:EXAS – Get Rating) last announced its quarterly earnings data on Tuesday, May 9th. The medical research company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.37. The firm had revenue of $602.00 million during the quarter, compared to analyst estimates of $543.18 million. Exact Sciences had a negative net margin of 23.49% and a negative return on equity of 16.64%. The business’s quarterly revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the business posted ($1.04) EPS. As a group, equities research analysts forecast that Exact Sciences Co. will post -2.24 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on EXAS shares. BTIG Research boosted their price objective on shares of Exact Sciences from $80.00 to $90.00 in a research note on Wednesday, May 10th. Bank of America boosted their price objective on shares of Exact Sciences from $80.00 to $88.00 in a research note on Wednesday, May 10th. Citigroup boosted their price objective on shares of Exact Sciences from $90.00 to $100.00 in a research note on Thursday, May 11th. Benchmark boosted their price target on shares of Exact Sciences from $54.00 to $78.00 and gave the stock a “buy” rating in a research note on Wednesday, March 15th. Finally, Craig Hallum raised shares of Exact Sciences from a “hold” rating to a “buy” rating and boosted their price target for the stock from $55.00 to $85.00 in a research note on Wednesday, May 10th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, Exact Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $79.13.

About Exact Sciences

(Get Rating)

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer and Oncotype DX. The company was founded on February 10, 1995, and is headquartered in Madison, WI.